A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of RO7079901 Administered Intravenously Both Alone and in Combination With Meropenem in Adult Healthy Volunteers

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of RO7079901 Administered Intravenously Both Alone and in Combination With Meropenem in Adult Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Meropenem (Primary) ; Nacubactam (Primary) ; RO 7049389
  • Indications Unspecified
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 20 Apr 2017 Status changed from recruiting to completed.
    • 15 Mar 2017 Planned End Date changed from 1 Oct 2017 to 31 Oct 2017.
    • 15 Mar 2017 Planned primary completion date changed from 1 Oct 2017 to 31 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top